炎症性肠病治疗中的选择性治疗形式
Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases.
作者信息
Kofla-Dłubacz Anna, Akutko Katarzyna, Krzesiek Elżbieta, Jamer Tatiana, Braksator Joanna, Grębska Paula, Pytrus Tomasz, Stawarski Andrzej
机构信息
2nd Department of Paediatrics, Gastroenterology and Nutrition, Faculty of Medicine, Wroclaw Medical University, M. Sklodowskiej-Curie Str. 50/52, 50-367 Wroclawl, Poland.
出版信息
J Clin Med. 2022 Feb 14;11(4):994. doi: 10.3390/jcm11040994.
Abstract
Selective interference with the functioning of the immune system consisting of the selective blockade of pro-inflammatory factors is a modern, promising, and developing strategy for the treatment of diseases resulting from dysregulation of the immune system, including inflammatory bowel disease. Inhibition of the TNF alpha pathway, group 12/23 cytokines, and lymphocyte migration is used in the treatment of severe or moderate ulcerative colitis and Crohn's disease. Intracellular signal transduction by influencing the phosphorylation of SAT (signal transducer and activator of transcription) proteins remains in clinical trials.
摘要
对由促炎因子的选择性阻断构成的免疫系统功能进行选择性干扰，是一种用于治疗由免疫系统失调引起的疾病（包括炎症性肠病）的现代、有前景且不断发展的策略。抑制肿瘤坏死因子α通路、第12/23组细胞因子和淋巴细胞迁移被用于治疗重度或中度溃疡性结肠炎和克罗恩病。通过影响信号转导及转录激活蛋白（SAT）的磷酸化进行细胞内信号转导仍处于临床试验阶段。
相似文献
1
Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases.炎症性肠病治疗中的选择性治疗形式
J Clin Med. 2022 Feb 14;11(4):994. doi: 10.3390/jcm11040994.
2
Biologic therapy for inflammatory bowel disease.炎症性肠病的生物治疗
Drugs. 2005;65(16):2253-86. doi: 10.2165/00003495-200565160-00002.
3
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.通过RAND方法评估炎症性肠病中免疫抑制药物的适用性：意大利炎症性肠病研究小组（IG-IBD）立场声明
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
4
Visceral adiposity and inflammatory bowel disease.内脏肥胖与炎症性肠病。
Int J Colorectal Dis. 2021 Nov;36(11):2305-2319. doi: 10.1007/s00384-021-03968-w. Epub 2021 Jun 9.
5
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?JAK 选择性治疗炎症性肠病：这在临床上有意义吗？
Gut. 2019 Oct;68(10):1893-1899. doi: 10.1136/gutjnl-2019-318448. Epub 2019 Jun 21.
6
Immune system alterations in patients with inflammatory bowel disease during remission.炎症性肠病缓解期患者的免疫系统改变
Medicina (Kaunas). 2008;44(1):27-33.
7
Systemic Molecular Mediators of Inflammation Differentiate Between Crohn's Disease and Ulcerative Colitis, Implicating Threshold Levels of IL-10 and Relative Ratios of Pro-inflammatory Cytokines in Therapy.炎症的系统分子介质可区分克罗恩病和溃疡性结肠炎，提示 IL-10 的阈值水平和治疗中促炎细胞因子的相对比值。
J Crohns Colitis. 2020 Jan 1;14(1):118-129. doi: 10.1093/ecco-jcc/jjz117.
8
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.英夫利昔单抗和其他抗肿瘤坏死因子 α 治疗药物治疗炎症性肠病。
BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.
9
Chemokine and cytokine levels in inflammatory bowel disease patients.炎症性肠病患者体内趋化因子和细胞因子水平
Cytokine. 2016 Jan;77:44-9. doi: 10.1016/j.cyto.2015.10.008. Epub 2015 Oct 29.
10
Inflammatory pathways of importance for management of inflammatory bowel disease.炎症性肠病治疗中重要的炎症通路。
World J Gastroenterol. 2014 Jan 7;20(1):64-77. doi: 10.3748/wjg.v20.i1.64.
引用本文的文献
1
Hemopexin and HO-1 induction during acute colitis in mice is dependent on interleukin-22.小鼠急性结肠炎期间血色素结合蛋白和血红素加氧酶-1的诱导依赖于白细胞介素-22。
Front Immunol. 2025 Jul 28;16:1614466. doi: 10.3389/fimmu.2025.1614466. eCollection 2025.
2
Synthesis and Bioevaluation of New Stable Derivatives of Chrysin-8--Glucoside That Modulate the Antioxidant Keap1/Nrf2/HO-1 Pathway in Human Macrophages.白杨素-8-O-葡萄糖苷新型稳定衍生物的合成及其生物活性评价：对人巨噬细胞中抗氧化Keap1/Nrf2/HO-1通路的调控作用
Pharmaceuticals (Basel). 2024 Oct 17;17(10):1388. doi: 10.3390/ph17101388.
3
Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease.新型生物制剂和小分子药物在炎症性肠病个体化治疗中的现状。
World J Gastroenterol. 2022 Dec 28;28(48):6888-6899. doi: 10.3748/wjg.v28.i48.6888.
4
Etiology of IBD-Is It Still a Mystery?炎症性肠病的病因：它仍然是个谜吗？
Int J Mol Sci. 2022 Oct 18;23(20):12445. doi: 10.3390/ijms232012445.
5
Special Issue "Clinical Advances in Chronic Intestinal Diseases Treatment".特刊“慢性肠道疾病治疗的临床进展”。
J Clin Med. 2022 Feb 25;11(5):1258. doi: 10.3390/jcm11051258.
本文引用的文献
1
Treatment of Inflammatory Bowel Disease: A Comprehensive Review.炎症性肠病的治疗：全面综述
Front Med (Lausanne). 2021 Dec 20;8:765474. doi: 10.3389/fmed.2021.765474. eCollection 2021.
2
Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment.JAK抑制剂在炎症性肠病治疗中的疗效、安全性及未来展望
J Clin Med. 2021 Nov 30;10(23):5660. doi: 10.3390/jcm10235660.
3
Etrolizumab for ulcerative colitis: beyond what meets the eye.艾托珠单抗治疗溃疡性结肠炎：表象之外
Lancet Gastroenterol Hepatol. 2022 Jan;7(1):2-4. doi: 10.1016/S2468-1253(21)00369-1. Epub 2021 Nov 17.
4
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.奥扎莫德用于溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.
5
Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.用于治疗炎症性肠病的抗整合素：当前证据与展望
Clin Exp Gastroenterol. 2021 Aug 24;14:333-342. doi: 10.2147/CEG.S293272. eCollection 2021.
6
Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease.儿童炎症性肠病生物治疗中治疗药物监测的进展
Front Pediatr. 2021 May 26;9:661536. doi: 10.3389/fped.2021.661536. eCollection 2021.
7
Positioning Biologic Therapies in the Management of Pediatric Inflammatory Bowel Disease.生物疗法在儿童炎症性肠病治疗中的定位
Gastroenterol Hepatol (N Y). 2020 Aug;16(8):400-414.
8
An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis.奥扎莫德治疗复发型多发性硬化症的疗效和安全性概述。
Drug Des Devel Ther. 2021 May 11;15:1993-2004. doi: 10.2147/DDDT.S240861. eCollection 2021.
9
Novel and Emerging Therapies for Inflammatory Bowel Disease.炎症性肠病的新型和新兴疗法
Front Pharmacol. 2021 Apr 14;12:651415. doi: 10.3389/fphar.2021.651415. eCollection 2021.
10
Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease.奥拉美珠单抗（sgp130Fc）治疗活动性炎症性肠病患者的白细胞介素-6 转导信号抑制作用。
Gastroenterology. 2021 Jun;160(7):2354-2366.e11. doi: 10.1053/j.gastro.2021.02.062. Epub 2021 Mar 2.
Zotero 插件